Sonidegib

It was approved for medical use in the United States and in the European Union in 2015 It is indicated for the treatment of adults with locally advanced basal-cell carcinoma that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. == Pharmacology ==

Sonidegib is administered by mouth. Common side effects include muscle spasms, hair loss, fatigue, abdominal pain, nausea, headache, and weight loss. Sonidegib binds to and inhibits smoothened to inhibit activation of the Hedgehog pathway. Sonidegib is primarily metabolized by CYP3A and is eliminated hepatically. ==Development==

It has been investigated as a potential treatment for: • Pancreatic cancer • Breast cancer • Basal cell carcinoma of the skin • Small cell lung cancer • Medulloblastoma • Advanced solid tumors (including ovarian, breast, pancreatic, stomach, oesophageal cancers and glioblastoma multiforme) • Acute leukemia and chronic myeloid leukemia • Myelofibrosis and essential thrombocythaemia It has demonstrated significant efficacy against melanoma in vitro and in vivo. It also demonstrated efficacy in a mouse model of pancreatic cancer. ==References==